Loading…
Skye Bioscience, Inc. is projected to decline to $0.7533 by 2027, a -9% move from its current price of $0.8285. SKYE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.7857 | $0.8274 | $0.8714 | -0.13% |
| May 30 | $0.768 | $0.8263 | $0.8891 | -0.26% |
| May 31 | $0.7545 | $0.8252 | $0.9026 | -0.39% |
| Jun 1 | $0.7431 | $0.8242 | $0.914 | -0.52% |
| Jun 2 | $0.7331 | $0.8231 | $0.924 | -0.66% |
| Jun 3 | $0.7241 | $0.822 | $0.9331 | -0.79% |
| Jun 4 | $0.7159 | $0.8209 | $0.9414 | -0.92% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.7159 | $0.8209 | $0.9414 | -0.92% |
| Week 2 | $0.6702 | $0.8134 | $0.9872 | -1.83% |
| Week 3 | $0.6358 | $0.8059 | $1.02 | -2.73% |
| Week 4 | $0.6072 | $0.7985 | $1.05 | -3.62% |
| Week 5 | $0.5825 | $0.7912 | $1.07 | -4.50% |
| Week 6 | $0.5606 | $0.784 | $1.10 | -5.38% |
| Week 7 | $0.5407 | $0.7768 | $1.12 | -6.24% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Skye Bioscience, Inc. is a clinical-stage biotechnology company focused on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate nimacimab is a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation.
The company was formerly Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
Skye Bioscience is headquartered in San Diego, California.
Skye Bioscience, Inc. (SKYE) is a healthcare stock with a current price of $0.8293 and a market cap of $29.14M. It ranks 4816 by market capitalization.
The year-by-year price forecast begins with 2026 an average of $0.8293, with a min of $0.577 and a max of $1.01, signaling potential near-term upside to around $1.01. The forecast continues through 2050, with the 2050 average at $3.87 and a max of $8.89, indicating meaningful long-term upside relative to today.
In 2029 the average is $1.07 (ROI 28.6%), rising to a 2030 average of $1.25 (ROI 51.1%) and a 2035 average of $1.46 (ROI 76.3%). The sequence projects continued gains into 2040 (avg $1.53, ROI 84.7%) and 2050 (avg $3.87, ROI 366.3%).
Overall, the forecast envisions a path from a near-term neutral stance toward a longer-term bullish trajectory, with higher average prices and substantial upside potential by 2050.
A major floor 36.9% below — a decisive break under it would weaken the trend.
The nearest floor, 13.7% below — buyers have tended to step in here.
The nearest ceiling, 27.9% above — a clean break opens room to run.
A major ceiling 46.4% above — clearing it would confirm fresh momentum.
Key SKYE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SKYE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7928 | Buy | $0.8068 | Buy |
| MA 10 | $0.7972 | Buy | $0.8072 | Buy |
| MA 20 | $0.8311 | Sell | $0.8155 | Buy |
| MA 50 | $0.7743 | Buy | $0.8149 | Buy |
| MA 100 | $0.8148 | Buy | $0.9493 | Sell |
| MA 200 | $1.54 | Sell | $1.44 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.40 | Neutral |
| Stoch RSI (14) | 66.33 | Neutral |
| CCI (20) | -3.47 | Neutral |
| Williams %R (14) | -37.70 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -3.94 | Sell |
| Bollinger %B (20,2) | 0.49 | Neutral |
| Stochastic %K (14) | 62.30 | Neutral |
| TRIX (15) | 0.08 | Buy |
| Awesome (5,34) | -0.04 | Sell |
| Ultimate (7,14,28) | 51.29 | Neutral |
| Momentum (10) | 0.01 | Buy |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.82 | Buy |
| ADX (14) | 11.91 | Neutral |
| ATR (14) | 0.04 | Info |
The 30-day technical picture is NEUTRAL, with RSI(14) at 50. The stock trades with a SMA50 of $0.7688 and a SMA200 of $1.57, indicating the price is above the short-term average but well below the longer-term average.
The 30-day range spans from a low of $0.5772 to a high of $1.19, providing nearby support at $0.715 and resistance at $1.06. The asset shows an elevated level of volatility, as indicated by an annualized volatility of 100%.
These indicators point to a cautious near-term stance, with potential for movement within a wide band as volatility remains a feature of the trading pattern.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.577 | $0.8285 | $1.02 | 0% | Neutral | |
| $0.5456 | $0.7533 | $1.12 | -9% | Neutral | |
| $0.6031 | $0.8817 | $1.40 | +6% | Neutral | |
| $0.70 | $1.07 | $1.78 | +30% | Bullish | |
| $0.778 | $1.25 | $2.16 | +51% | Bullish | |
| $0.7271 | $1.22 | $2.17 | +47% | Bullish | |
| $0.6495 | $1.13 | $2.08 | +37% | Bullish | |
| $0.5931 | $1.07 | $2.03 | +30% | Bullish | |
| $0.5847 | $1.10 | $2.13 | +33% | Bullish | |
| $0.7648 | $1.49 | $2.95 | +80% | Bullish | |
| $0.7041 | $1.56 | $3.39 | +89% | Bullish | |
| $1.76 | $3.91 | $9.00 | +372% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.577 | $0.8285 | $0.9737 | +0.00% |
| June 2026 | $0.6247 | $0.7482 | $0.9278 | -9.69% |
| July 2026 | $0.6036 | $0.7348 | $0.9339 | -1.79% |
| August 2026 | $0.6021 | $0.7424 | $0.9615 | +1.04% |
| September 2026 | $0.5563 | $0.6934 | $0.9116 | -6.61% |
| October 2026 | $0.5313 | $0.6688 | $0.8914 | -3.54% |
| November 2026 | $0.5688 | $0.7222 | $0.974 | +7.98% |
| December 2026 | $0.5837 | $0.7474 | $1.02 | +3.48% |
Click any year to see its month-by-month SKYE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, SKYE could reach as high as $1.02, with a base case around $0.8285 and support toward $0.577 — roughly 0% from $0.8285. A consolidation phase looks the most probable path here.
Expect SKYE to range from $0.5456 to $1.12 through 2027. The $0.7533 average target implies a -9% move from current prices. That is -9% versus the projected 2026 average. Price action looks broadly range-bound.
The SKYE price prediction for 2028 points to an average of $0.8817 (low $0.6031, high $1.40) — a potential gain of +6% on today's $0.8285. A consolidation phase looks the most probable path here.
In 2029, SKYE is projected to trade between $0.70 and $1.78, averaging $1.07 — a potential gain of +30% from today's $0.8285. That is up +22% on the projected 2028 average. Momentum favours further upside here.
Skye Bioscience, Inc.'s 2030 outlook centres on $1.25, within a $0.778 to $2.16 range. That is up +16% on the projected 2029 average. That marks a +51% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, SKYE could reach as high as $2.17, with a base case around $1.22 and support toward $0.7271 — roughly +47% from $0.8285. Momentum favours further upside here.
Expect SKYE to range from $0.6495 to $2.08 through 2032. The $1.13 average target implies a +37% move from current prices. That is -7% versus the projected 2031 average. Buyers look set to stay in control over this stretch.
The SKYE price prediction for 2033 points to an average of $1.07 (low $0.5931, high $2.03) — a potential gain of +30% on today's $0.8285. Momentum favours further upside here.
In 2034, SKYE is projected to trade between $0.5847 and $2.13, averaging $1.10 — a potential gain of +33% from today's $0.8285. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Skye Bioscience, Inc.'s 2035 outlook centres on $1.49, within a $0.7648 to $2.95 range. That is up +36% on the projected 2034 average. That marks a +80% change versus current levels. Momentum favours further upside here.
By 2040, SKYE could reach as high as $3.39, with a base case around $1.56 and support toward $0.7041 — roughly +89% from $0.8285. Buyers look set to stay in control over this stretch.
Expect SKYE to range from $1.76 to $9.00 through 2050. The $3.91 average target implies a +372% move from current prices. That is up +150% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in SKYE today (≈ 1,207.000604 SKYE) could be worth
$4,722.65
+$3,722.65 (+372%) by 2050 · US Dollar
Based on the average projected SKYE price of $3.91 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SKYEwould be worth at today's price.
$1,000 invested in SKYE on May 27, 2025 (≈ 454.545445 SKYE) would be worth
$376.59
-$623.41 (-62.3%) today · 0.38× · US Dollar
Based on a SKYE entry price of $2.2 vs. today's $0.8285.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.769 | $1,077.37 | +7.7% |
| 1 month ago | $1.06 | $781.6 | -21.8% |
| 3 months ago | $0.771 | $1,074.58 | +7.5% |
| 6 months ago | $1.31 | $632.44 | -36.8% |
| 1 year ago | $2.2 | $376.59 | -62.3% |
| All time (5.0y) ago | $42.25 | $19.61 | -98.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SKYE forecast.
Our base-case forecast reaches $1.70 around 2050.
Implied market cap at $1.70: $59.74M
The multi-year forecast paints a bullish path beyond the near term. The year-by-year outlook shows 2029 at an average of $1.07 with ROI 28.6% and 2020 onwards moving toward higher levels, including 2030 at $1.25 (ROI 51.1%), 2031 at $1.23 (ROI 47.8%), and 2032 at $1.10 (ROI 32.9%). The trajectory remains positive through 2033 ($1.06, ROI 27.4%), 2034 ($1.09, ROI 31.8%), and 2035 ($1.46, ROI 76.3%), with 2040 averaging $1.53 (ROI 84.7%) and 2050 at $3.87 (ROI 366.3%).
There is a brief period of modest downside in 2027 (min $0.5294, avg $0.7363, max $1.11; ROI -11.2%), followed by a bullish decade that moves higher toward 2050. These are estimates, not guarantees, and reflect potential upside as well as year-to-year volatility. Investors should weigh the long-run upside against near-term variability and the inherent uncertainties of early-stage biotechnology equities.
Tap a question to reveal the answer.
2030 avg $1.25 with ROI 51.1%; min $0.7701; max $2.19.
The forecast shows bullish sentiment from 2029 onward, with 2029 avg $1.07 (ROI 28.6%), 2030 avg $1.25 (ROI 51.1%), and 2050 avg $3.87 (ROI 366.3%), but 2027 records a negative ROI of -11.2%. These are estimates and involve volatility and risk.
Yes. The 2035 max is $2.93, which exceeds $2.00, indicating the target is within the projected range.
Current price is $0.8293 and market cap is $29.14M.
The 30-dayRange low is $0.5772 and high is $1.19.
Skye Bioscience, Inc. Community Discussion
0Share your Skye Bioscience, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.